| Pathway | n | r | z | | Calcium Regulation in the Cardiac Cell | 136 | 136 | NaN |
| Urea cycle and metabolism of amino groups | 19 | 19 | NaN |
| GPCRs, Other | 59 | 59 | NaN |
| Glutathione metabolism | 17 | 17 | NaN |
| Gene regulatory network modelling somitogenesis | 9 | 9 | NaN |
| Hypothetical Network for Drug Addiction | 31 | 31 | NaN |
| TGF Beta Signaling Pathway | 52 | 52 | NaN |
| Alzheimers Disease | 77 | 77 | NaN |
| Regulation of toll-like receptor signaling pathway | 119 | 119 | NaN |
| Constitutive Androstane Receptor Pathway | 25 | 25 | NaN |
| Secretion of Hydrochloric Acid in Parietal Cells | 2 | 2 | NaN |
| Trans-sulfuration pathway | 10 | 10 | NaN |
| mRNA Processing | 125 | 125 | NaN |
| Pentose Phosphate Pathway | 7 | 7 | NaN |
| Focal Adhesion | 184 | 184 | NaN |
| p38 MAPK Signaling Pathway | 34 | 34 | NaN |
| TCA Cycle and PDHc | 16 | 16 | NaN |
| Bladder Cancer | 30 | 30 | NaN |
| Oxidative phosphorylation | 51 | 51 | NaN |
| Cell Differentiation - Index | 10 | 10 | NaN |
| Parkin-Ubiquitin Proteasomal System pathway | 67 | 67 | NaN |
| Cori Cycle | 12 | 12 | NaN |
| Hypoxia-mediated EMT and Stemness | 2 | 2 | NaN |
| Osteoblast Signaling | 11 | 11 | NaN |
| Fluoropyrimidine Activity | 31 | 31 | NaN |
| TSLP Signaling Pathway | 45 | 45 | NaN |
| Oxidation by Cytochrome P450 | 48 | 48 | NaN |
| Integrated Pancreatic Cancer Pathway | 192 | 192 | NaN |
| TWEAK Signaling Pathway | 42 | 42 | NaN |
| Globo Sphingolipid Metabolism | 22 | 22 | NaN |
| Complement and Coagulation Cascades | 47 | 47 | NaN |
| Semaphorin interactions | 61 | 61 | NaN |
| Diurnally Regulated Genes with Circadian Orthologs | 46 | 46 | NaN |
| Interactome of polycomb repressive complex 2 (PRC2) | 16 | 16 | NaN |
| Folate Metabolism | 50 | 50 | NaN |
| Membrane Trafficking | 76 | 76 | NaN |
| Statin Pathway | 22 | 22 | NaN |
| Interferon type I signaling pathways | 54 | 54 | NaN |
| PDGF Pathway | 38 | 38 | NaN |
| AGE/RAGE pathway | 62 | 62 | NaN |
| Alanine and aspartate metabolism | 10 | 10 | NaN |
| Myometrial Relaxation and Contraction Pathways | 146 | 146 | NaN |
| Cardiac Progenitor Differentiation | 46 | 46 | NaN |
| ErbB Signaling Pathway | 52 | 52 | NaN |
| Mitochondrial LC-Fatty Acid Beta-Oxidation | 17 | 17 | NaN |
| Complement Activation, Classical Pathway | 10 | 10 | NaN |
| AMPK Signaling | 64 | 64 | NaN |
| Catalytic cycle of mammalian FMOs | 4 | 4 | NaN |
| TFs Regulate miRNAs related to cardiac hypertrophy | 8 | 8 | NaN |
| DDX1 as a regulatory component of the Drosha microprocessor | 7 | 7 | NaN |
| Hair Follicle Development: Induction (Part 1 of 3) | 42 | 42 | NaN |
| Blood Clotting Cascade | 13 | 13 | NaN |
| IL1 and megakaryotyces in obesity | 20 | 20 | NaN |
| FSH signaling pathway | 23 | 23 | NaN |
| Synaptic Vesicle Pathway | 44 | 44 | NaN |
| T-Cell Receptor and Co-stimulatory Signaling | 26 | 26 | NaN |
| Tamoxifen metabolism | 15 | 15 | NaN |
| Integrated Cancer pathway | 44 | 44 | NaN |
| Amino acid conjugation of benzoic acid | 3 | 3 | NaN |
| Heart Development | 41 | 41 | NaN |
| Angiogenesis | 24 | 24 | NaN |
| Serotonin Transporter Activity | 11 | 11 | NaN |
| Codeine and Morphine Metabolism | 8 | 8 | NaN |
| Methylation Pathways | 7 | 7 | NaN |
| mir34a and TGIF2 in osteoclastogenesis | 1 | 1 | NaN |
| Extracellular vesicle-mediated signaling in recipient cells | 29 | 29 | NaN |
| Deregulation of Rab and Rab Effector Genes in Bladder Cancer | 16 | 16 | NaN |
| Parkinsons Disease Pathway | 39 | 39 | NaN |
| Spinal Cord Injury | 100 | 100 | NaN |
| Eukaryotic Transcription Initiation | 41 | 41 | NaN |
| Nucleotide GPCRs | 9 | 9 | NaN |
| Vitamin B12 Metabolism | 37 | 37 | NaN |
| Wnt Signaling Pathway and Pluripotency | 96 | 96 | NaN |
| Adipogenesis | 120 | 120 | NaN |
| Nicotine Metabolism | 2 | 2 | NaN |
| Small Ligand GPCRs | 13 | 13 | NaN |
| Arrhythmogenic Right Ventricular Cardiomyopathy | 64 | 64 | NaN |
| EPO Receptor Signaling | 25 | 25 | NaN |
| RalA downstream regulated genes | 12 | 12 | NaN |
| EGF/EGFR Signaling Pathway | 159 | 159 | NaN |
| Selenium Micronutrient Network | 63 | 63 | NaN |
| EBV LMP1 signaling | 22 | 22 | NaN |
| Differentiation Pathway | 44 | 44 | NaN |
| Glucose Homeostasis | 0 | 0 | NaN |
| TSH signaling pathway | 64 | 64 | NaN |
| Insulin Signaling | 158 | 158 | NaN |
| Wnt Signaling Pathway | 62 | 62 | NaN |
| G1 to S cell cycle control | 66 | 66 | NaN |
| IL17 signaling pathway | 26 | 26 | NaN |
| Monoamine GPCRs | 23 | 23 | NaN |
| IL-1 signaling pathway | 55 | 55 | NaN |
| B Cell Receptor Signaling Pathway | 94 | 94 | NaN |
| RNA interference | 5 | 5 | NaN |
| Interleukin-11 Signaling Pathway | 43 | 43 | NaN |
| Gastric acid production | 1 | 1 | NaN |
| Alpha 6 Beta 4 signaling pathway | 33 | 33 | NaN |
| Acetylcholine Synthesis | 5 | 5 | NaN |
| Oxytocin signaling | 4 | 4 | NaN |
| TCA Cycle | 17 | 17 | NaN |
| Neurotransmitter Clearance In The Synaptic Cleft | 4 | 4 | NaN |
| Gastric cancer network 2 | 30 | 30 | NaN |
| Proteasome Degradation | 60 | 60 | NaN |
| TarBasePathway | 12 | 12 | NaN |
| ATM Signaling Pathway | 41 | 41 | NaN |
| Cytokines and Inflammatory Response | 16 | 16 | NaN |
| Type III interferon signaling | 7 | 7 | NaN |
| Sphingolipid Metabolism | 20 | 20 | NaN |
| Mesodermal Commitment Pathway | 67 | 67 | NaN |
| Translation Factors | 50 | 50 | NaN |
| Physiological and Pathological Hypertrophy of the Heart | 23 | 23 | NaN |
| Cholesterol Biosynthesis | 15 | 15 | NaN |
| Primary Focal Segmental Glomerulosclerosis FSGS | 69 | 69 | NaN |
| Effects of Nitric Oxide | 6 | 6 | NaN |
| Cardiac Hypertrophic Response | 53 | 53 | NaN |
| Homologous recombination | 13 | 13 | NaN |
| Heme Biosynthesis | 9 | 9 | NaN |
| Eicosanoid Synthesis | 18 | 18 | NaN |
| NLR Proteins | 8 | 8 | NaN |
| Nucleotide Metabolism | 19 | 19 | NaN |
| Glucuronidation | 11 | 11 | NaN |
| SIDS Susceptibility Pathways | 144 | 144 | NaN |
| Gastric Cancer Network 1 | 28 | 28 | NaN |
| BDNF signaling pathway | 142 | 142 | NaN |
| Regulation of Actin Cytoskeleton | 139 | 139 | NaN |
| Apoptosis | 81 | 81 | NaN |
| TGF beta Signaling Pathway | 129 | 129 | NaN |
| IL-9 Signaling Pathway | 15 | 15 | NaN |
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | 20 | 20 | NaN |
| IL-2 Signaling Pathway | 40 | 40 | NaN |
| Estrogen Receptor Pathway | 12 | 12 | NaN |
| miRNA Biogenesis | 6 | 6 | NaN |
| Glial Cell Differentiation | 7 | 7 | NaN |
| Pilocytic astrocytoma | 4 | 4 | NaN |
| Notch Signaling Pathway | 58 | 58 | NaN |
| RANKL/RANK Signaling Pathway | 54 | 54 | NaN |
| Allograft Rejection | 56 | 56 | NaN |
| Cell Cycle | 101 | 101 | NaN |
| Structural Pathway of Interleukin 1 (IL-1) | 48 | 48 | NaN |
| Osteopontin Signaling | 12 | 12 | NaN |
| Wnt Signaling Pathway Netpath | 50 | 50 | NaN |
| Aryl Hydrocarbon Receptor Pathway | 36 | 36 | NaN |
| Endochondral Ossification | 57 | 57 | NaN |
| Steroid Biosynthesis | 8 | 8 | NaN |
| Neural Crest Differentiation | 91 | 91 | NaN |
| Ovarian Infertility Genes | 31 | 31 | NaN |
| ID signaling pathway | 15 | 15 | NaN |
| Estrogen metabolism | 15 | 15 | NaN |
| Arachidonate Epoxygenase / Epoxide Hydrolase | 6 | 6 | NaN |
| Serotonin Receptor 4/6/7 and NR3C Signaling | 17 | 17 | NaN |
| Glycerophospholipid Biosynthetic Pathway | 21 | 21 | NaN |
| ACE Inhibitor Pathway | 10 | 10 | NaN |
| Butyrate-induced histone acetylation | 2 | 2 | NaN |
| Synthesis and Degradation of Ketone Bodies | 4 | 4 | NaN |
| One carbon donor | 1 | 1 | NaN |
| Vitamin D Metabolism | 9 | 9 | NaN |
| Thyroxine (Thyroid Hormone) Production | 4 | 4 | NaN |
| G13 Signaling Pathway | 36 | 36 | NaN |
| GPCRs, Class B Secretin-like | 19 | 19 | NaN |
| DNA Replication | 42 | 42 | NaN |
| Drug Induction of Bile Acid Pathway | 12 | 12 | NaN |
| Fatty Acid Omega Oxidation | 11 | 11 | NaN |
| HIF1A and PPARG regulation of glycolysis | 0 | 0 | NaN |
| PCSK9-mediated LDLR degradation | 1 | 1 | NaN |
| Histone Modifications | 55 | 55 | NaN |
| MAPK Cascade | 29 | 29 | NaN |
| Prostaglandin Synthesis and Regulation | 25 | 25 | NaN |
| miRNA Regulation of DNA Damage Response | 74 | 74 | NaN |
| IL-4 Signaling Pathway | 53 | 53 | NaN |
| G Protein Signaling Pathways | 87 | 87 | NaN |
| TOR Signaling | 33 | 33 | NaN |
| IL-6 signaling pathway | 41 | 41 | NaN |
| DNA Damage Response | 68 | 68 | NaN |
| MAPK Signaling Pathway | 160 | 160 | NaN |
| Hedgehog Signaling Pathway | 15 | 15 | NaN |
| Phospholipid biosynthesis | 0 | 0 | NaN |
| IL-7 Signaling Pathway | 23 | 23 | NaN |
| Dopamine metabolism | 11 | 11 | NaN |
| Type II diabetes mellitus | 19 | 19 | NaN |
| GPCRs, Class C Metabotropic glutamate, pheromone | 15 | 15 | NaN |
| Signaling Pathways in Glioblastoma | 81 | 81 | NaN |
| miRNAs involved in DNA damage response | 18 | 18 | NaN |
| Farnesoid X Receptor Pathway | 12 | 12 | NaN |
| Mismatch repair | 9 | 9 | NaN |
| Glycogen Metabolism | 36 | 36 | NaN |
| Peptide GPCRs | 43 | 43 | NaN |
| Kit receptor signaling pathway | 59 | 59 | NaN |
| Liver X Receptor Pathway | 9 | 9 | NaN |
| Selenium Metabolism and Selenoproteins | 39 | 39 | NaN |
| TNF alpha Signaling Pathway | 88 | 88 | NaN |
| Iron metabolism in placenta | 12 | 12 | NaN |
| Vitamin A and Carotenoid Metabolism | 37 | 37 | NaN |
| Glycine Metabolism | 3 | 3 | NaN |
| Fatty Acid Biosynthesis | 22 | 22 | NaN |
| Triacylglyceride Synthesis | 19 | 19 | NaN |
| Arylamine metabolism | 4 | 4 | NaN |
| Monoamine Transport | 25 | 25 | NaN |
| Estrogen signaling pathway | 22 | 22 | NaN |
| Pathogenic Escherichia coli infection | 52 | 52 | NaN |
| Aflatoxin B1 metabolism | 7 | 7 | NaN |
| TP53 Network | 21 | 21 | NaN |
| Nanoparticle-mediated activation of receptor signaling | 27 | 27 | NaN |
| Apoptosis-related network due to altered Notch3 in ovarian cancer | 53 | 53 | NaN |
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | 13 | 13 | NaN |
| Notch Signaling Pathway | 43 | 43 | NaN |
| DNA Damage Response (only ATM dependent) | 109 | 109 | NaN |
| Trans-sulfuration and one carbon metabolism | 30 | 30 | NaN |
| Sulindac Metabolic Pathway | 5 | 5 | NaN |
| Irinotecan Pathway | 12 | 12 | NaN |
| Oxidative Stress | 28 | 28 | NaN |
| Ganglio Sphingolipid Metabolism | 17 | 17 | NaN |
| Differentiation of white and brown adipocyte | 23 | 23 | NaN |
| Senescence and Autophagy in Cancer | 99 | 99 | NaN |
| Iron uptake and transport | 99 | 99 | NaN |
| Glycolysis and Gluconeogenesis | 43 | 43 | NaN |
| Nuclear Receptors in Lipid Metabolism and Toxicity | 25 | 25 | NaN |
| Mitochondrial Gene Expression | 19 | 19 | NaN |
| Arylhydrocarbon receptor (AhR) signaling pathway | 24 | 24 | NaN |
| Transcriptional activation by NRF2 | 15 | 15 | NaN |
| NAD Biosynthesis II (from tryptophan) | 7 | 7 | NaN |
| Biogenic Amine Synthesis | 10 | 10 | NaN |
| BMP Signalling and Regulation | 12 | 12 | NaN |
| Osteoclast Signaling | 14 | 14 | NaN |
| Toll-like receptor signaling pathway | 81 | 81 | NaN |
| Non-homologous end joining | 8 | 8 | NaN |
| Retinoblastoma (RB) in Cancer | 88 | 88 | NaN |
| Sulfation Biotransformation Reaction | 15 | 15 | NaN |
| Aryl Hydrocarbon Receptor | 45 | 45 | NaN |
| FAS pathway and Stress induction of HSP regulation | 41 | 41 | NaN |
| Signal Transduction of S1P Receptor | 25 | 25 | NaN |
| Regulation of Microtubule Cytoskeleton | 44 | 44 | NaN |
| Cytoplasmic Ribosomal Proteins | 87 | 87 | NaN |
| Ectoderm Differentiation | 134 | 134 | NaN |
| Signaling of Hepatocyte Growth Factor Receptor | 34 | 34 | NaN |
| Corticotropin-releasing hormone | 86 | 86 | NaN |
| SREBF and miR33 in cholesterol and lipid homeostasis | 16 | 16 | NaN |
| IL-5 Signaling Pathway | 38 | 38 | NaN |
| Leptin signaling pathway | 75 | 75 | NaN |
| TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | 5 | 5 | NaN |
| MicroRNAs in cardiomyocyte hypertrophy | 80 | 80 | NaN |
| Metastatic brain tumor | 7 | 7 | NaN |
| Phase I biotransformations, non P450 | 7 | 7 | NaN |
| Lidocaine metabolism | 2 | 2 | NaN |
| GPCRs, Class A Rhodopsin-like | 137 | 137 | NaN |
| Peroxisomal beta-oxidation of tetracosanoyl-CoA | 4 | 4 | NaN |
| Fatty Acid Beta Oxidation | 31 | 31 | NaN |
| One Carbon Metabolism | 26 | 26 | NaN |
| Amino acid conjugation | 0 | 0 | NaN |
| miRNA targets in ECM and membrane receptors | 22 | 22 | NaN |
| Integrin-mediated Cell Adhesion | 96 | 96 | NaN |
| Apoptosis Modulation and Signaling | 86 | 86 | NaN |
| Dopaminergic Neurogenesis | 23 | 23 | NaN |
| IL-3 Signaling Pathway | 44 | 44 | NaN |
| Nicotine Activity on Chromaffin Cells | 4 | 4 | NaN |
| Neurotransmitter Release Cycle | 13 | 13 | NaN |
| Nuclear Receptors | 36 | 36 | NaN |
| NRF2 pathway | 121 | 121 | NaN |
| TCR Signaling Pathway | 79 | 79 | NaN |
| Tryptophan metabolism | 39 | 39 | NaN |
| SRF and miRs in Smooth Muscle Differentiation and Proliferation | 11 | 11 | NaN |
| Apoptosis Modulation by HSP70 | 19 | 19 | NaN |
| SREBP signalling | 64 | 64 | NaN |
| Influenza A virus infection | 1 | 1 | NaN |
| Inflammatory Response Pathway | 19 | 19 | NaN |
| Endothelin Pathways | 26 | 26 | NaN |
| Amyotrophic lateral sclerosis (ALS) | 36 | 36 | NaN |
| Felbamate Metabolism | 2 | 2 | NaN |
| NOD pathway | 37 | 37 | NaN |
| Type II interferon signaling (IFNG) | 30 | 30 | NaN |
| Serotonin Receptor 2 and STAT3 Signaling | 4 | 4 | NaN |
| Nicotine Activity on Dopaminergic Neurons | 17 | 17 | NaN |
| Electron Transport Chain | 89 | 89 | NaN |
| Colchicine Metabolic Pathway | 1 | 1 | NaN |
| Hypertrophy Model | 18 | 18 | NaN |
| Endoderm Differentiation | 63 | 63 | NaN |
| Folate-Alcohol and Cancer Pathway | 8 | 8 | NaN |
| Benzo(a)pyrene metabolism | 8 | 8 | NaN |
| Glucocorticoid & Mineralcorticoid Metabolism | 6 | 6 | NaN |
| Oncostatin M Signaling Pathway | 61 | 61 | NaN |
| Polyol Pathway | 3 | 3 | NaN |
| PPAR Alpha Pathway | 20 | 20 | NaN |
| Diclofenac Metabolic Pathway | 4 | 4 | NaN |
| Striated Muscle Contraction | 31 | 31 | NaN |
| Androgen receptor signaling pathway | 87 | 87 | NaN |
| Integrated Breast Cancer Pathway | 159 | 159 | NaN |
| Matrix Metalloproteinases | 19 | 19 | NaN |
| Metapathway biotransformation | 137 | 137 | NaN |
| miRs in Muscle Cell Differentiation | 25 | 25 | NaN |